摘要
目的 探讨Smo、胶质瘤相关癌基因同源蛋白2(Gli2)及叉头框转录因子M1(FoxM1)对神经胶质瘤诊断和预后的评估价值。方法 取80例神经胶质瘤标本为神经胶质瘤组,60例正常脑组织标本为正常组。免疫组化法检测两组Smo、Gli2、FoxM1表达水平,分析其与神经胶质瘤患者临床病理特征的关系;Kaplan-Meier生存曲线分析不同Smo、Gli2、FoxM1表达水平神经胶质瘤患者预后的差异,分析影响神经胶质瘤预后的相关因素。结果 神经胶质瘤组织Smo、Gli2、FoxM1高表达率均高于正常脑组织,且随神经胶质瘤患者组织学分级升高而表达率增高(P<0.05)。不同组织学分级、不同Smo、Gli2、FoxM1表达水平的神经胶质瘤患者5年生存率存在显著差异(P<0.05)。组织学Ⅲ~Ⅳ级、Smo高表达、Gli2高表达、FoxM1高表达是神经胶质瘤预后的危险因素(P<0.05)。结论Smo、Gli2、FoxM1高表达是神经胶质瘤预后的危险因素,三者有望作为神经胶质瘤诊断和预后的判断指标。
Aim To investigate the value of Smoothened(Smo),glioma-related oncogene homolog 2(Gli2)and forkhead box transcription factor M1(FoxM1)in the diagnosis and prognosis of glioma.Methods 80 cases of glioma samples were taken as glioma group and 60 cases of normal brain tissue samples as normal group.The expression levels of Smo,Gli2 and FoxM1 in the two groups were detected by immunohistochemistry,and the relationship between the expression levels and the clinicopathological characteristics of glioma patients was analyzed.Kaplan-Meier survival curve was used to analyze the difference in the prognosis of glioma patients with different levels of expression of Smo,Gli2 and FoxM1,and the related factors affecting the prognosis of glioma were analyzed.Results The high expression rate of Smo,Gli2 and FoxM1 in glioma tissue was higher than that in normal brain tissue,and the expression rate increased with the increase of histological grade of glioma patients(P<0.05).The 5-year survival rate of glioma patients with different histological grades and different expressions of Smo,Gli2 and FoxM1 was significantly different(P<0.05).Histological gradeⅢ-Ⅳ,high expression of Smo,high expression of Gli2 and high expression of FoxM1 were risk factors for the prognosis of glioma(P<0.05).Conclusion The high expression of Smo,Gli2 and FoxM1 are risk factors for the prognosis of glioma,and they are expected to be used as indicators for the diagnosis and prognosis of glioma.
作者
肖仕和
李钢
周奋
刘珍
刘仲海
XIAO Shihe;LI Gang;ZHOU Fen;LIU Zhen;LIU Zhonghai(Department of Neurosurgery,Hainan Third Peoples Hospital,Sanya 572000,Hainan,China)
出处
《中南医学科学杂志》
CAS
2023年第2期234-237,共4页
Medical Science Journal of Central South China
基金
海南省卫生健康行业科研项目(20A200300)。
